Sol Gel Technologies Ltd (SLGL NASDAQ) stock market data APIs
$24.9056
-0.83(-3.3%)
as of September 12, 2025
Try our APIs with
free plan!
Sol Gel Technologies Ltd Financial Data Overview
Price chart is built with
Anychart
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Prev. Close
24.9056
Open
24.0748
High
24.9139
Low
23.0164
52 wk Range
4.006-30
Market Cap
69 115 K
Shares Outstanding
2 786 K
Revenue
23 931 K
EPS
-1.57
Beta
1.267
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sol Gel Technologies Ltd data using free add-ons & libraries
Get Sol Gel Technologies Ltd Fundamental Data
Sol Gel Technologies Ltd Fundamental data includes:
- Net Revenue: 23 931 K
- EBITDA: -4 590 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-15
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sol Gel Technologies Ltd News
New
What Does Health Canada's EPSOLAY Approval Mean For Sol-Gel Technologies Stock?
(RTTNews) - Sol-Gel Technologies Ltd. (SLGL) has notched a major regulatory win with Health Canada's approval of EPSOLAY, a topical cream for the treatment of inflammatory lesions of rosacea in adults...
Sol-Gel announces Health Canada approval of EPSOLAY
* Sol-Gel Technologies (NASDAQ:SLGL [https://seekingalpha.com/symbol/SLGL]) said on Thursday that Health Canada has issued [https://seekingalpha.com/pr/20220823-sol-gel-announces-health-canada-appro...
Sol Gel Tech earnings beat by $4.84, revenue topped estimates
Investing.com - Sol Gel Tech (NASDAQ: SLGL) reported second quarter EPS of $4.1700, $4.84 better than the analyst estimate of $-0.6700. Revenue for the quarter came in at $17.26M versus the consensus ...
Sol-Gel Technologies GAAP EPS of -$1.57, revenue of $5.89M
* Sol-Gel Technologies press release [https://seekingalpha.com/pr/20202388-sol-gel-reports-second-quarter-2025-financial-results-and-provides-corporate-updates] (NASDAQ:SLGL [https://seekingalpha.co...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
